An observational study in Type 1 Diabetes (T1D), sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus, Type 1 · University Hospital, Grenoble.
Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, this one is one of 2 that started in 2025, is one of 7 observational ones, and was the 17th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 5
First in 2003; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 100 is below the median of 125 across 791 observational studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 42 across the 11 interventional studies, 100 across the 7 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Diabetes Mellitus, Type 1 by University Hospital, Grenoble, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background: The management of type 1 diabetes (T1D) relies on exogenous insulin administration to compensate for the lack of endogenous insulin production. Optimal glycemic control, essential for preventing long-term complications, requires precise insulin dose adjustments based on carbohydrate intake. Functional insulin therapy (FIT) allows for flexibility in insulin dosing according to carbohydrate consumption, thereby reducing the dietary constraints previously imposed on patients. However, this approach requires increased attention to dietary intake. Individuals with T1D already have a heightened risk of developing eating disorders (EDs). We hypothesize that the dietary knowledge required for FIT may contribute to rigid eating behaviors, thereby increasing the risk of EDs.
Objective: This prospective monocentric study aims to determine whether dietary knowledge related to FIT is associated with an increased risk of EDs in individuals with T1D.
Methods: The primary outcome measure is the correlation between the Gluciquizz score (a validated tool assessing FIT knowledge) and the risk of EDs, evaluated using the DEPS-R questionnaire (a validated screening tool for ED risk in T1D patients). In addition to this quantitative analysis, a qualitative study will be conducted through semi-structured interviews to explore in greater depth the patients' experiences, their relationship with food, and their perceptions of FIT-related requirements.
Perspectives: This study aims to improve the understanding of the impact of FIT on ED risk in T1D. The findings may help identify at-risk patient profiles and enhance therapeutic education and patient management by integrating ED risk considerations. The qualitative approach will provide further insight into patients' individual experiences, facilitating recommendations tailored to their specific needs.
STUDY DESCRIPTION
This is a Type 3 study under the Jardé law, involving human subjects:
Observational study Prospective design Monocentric National scope
We selected this study design to minimize participant burden (data collection conducted online, by phone, or via videoconference, eliminating the need for patient travel). Recruitment through patient association websites and social media will enable a national reach.
The study will take place in four phases:
Recruitment Videoconference for a questionnaire on FIT-related dietary knowledge and ED risk assessment Self-administered online questionnaire Videoconference interview
SELECTION AND INCLUSION VISIT
If the participant wishes to join the study, they can either scan the QR code or visit the web link provided in the recruitment announcement. This QR code or link will redirect to a page detailing the study, the eligibility criteria that the participant must complete, and the information notice. The participant will enter their email address in the designated field and will also have the option to download the information notice if they wish.
Once this step is completed, the principal investigator will verify the eligibility criteria. If the participant meets the criteria, they will receive an email containing the necessary information for the next steps of the study:
Non-opposition letter - Part 1 A personal identifier number (formatted as initials + number, e.g., LA01) to pseudonymize questionnaire and self-reported responses A calendar allowing them to indicate their preferred date for the videoconference A link to access the videoconference
To ensure that the participant fully understands the study procedures, the clinical research associate (CRA) will go over the project details during the first videoconference and address any questions. The CRA will also check that the non-opposition form has been properly completed before integrating it into the study records.
If the participant does not meet the eligibility criteria, they will receive an email notifying them of their ineligibility.
The principal investigator will maintain a correspondence table containing the participant's name, surname, email address, and personal identifier number.
Participants will be fully and transparently informed in clear and understandable terms about the study objectives, the nature of the collected data, and their right to withdraw their consent at any time. The investigator must also inform participants about the opinion issued by the Ethics Committee (Comité de Protection des Personnes - CPP).
Participants can exercise their right to oppose the processing of their health data for research purposes at any time by contacting either the research coordinator or the institution responsible for the data. The institution is committed to responding to such requests within a maximum of two months.
FOLLOW-UP VISITS
The study will be conducted in three distinct phases:
First Phase: Videoconference for Questionnaire Completion
A clinical research associate (CRA) will contact the participant to administer the questionnaires. The CRA will directly enter the participant's responses into the Redcap online platform.
At the end of this interview, the investigator will invite participants to take part in the qualitative phase of the study (third phase: semi-structured videoconference interview). Participants will be progressively included until data saturation is reached.
If the participant agrees, the investigator will send a second email with a second non-opposition form - Part 2 (Appendix 4) for participation in the qualitative interview.
For all participants, a Redcap platform link will be emailed to them to complete the self-reported questionnaires.
Second Phase: Online Self-Questionnaires
Participants will receive a link to complete self-administered questionnaires directly on Redcap. Contact information for the CRA or investigator will be provided in case of technical issues.
This interview will be semi-structured and will follow the interview guide provided in Appendix 12. Participants will be included in this phase until data saturation is reached.
For the first and third phases, we have chosen to conduct interviews via the BigBlueButton videoconferencing platform, which is GDPR-compliant. We aim to use a platform that is user-friendly and free for participants.
Since BigBlueButton is integrated with the Université Grenoble Alpes information system, no additional identification data will be processed. The following personal data-voice and image-will be recorded by the interview organizer.
If the recording feature is activated, participants will be explicitly notified via a specific message. The recordings will be used exclusively for the transcription of data.
We aim to include patients with type 1 diabetes (T1D) in France. Participants will be enrolled in the study regardless of their current treatment.
We will reach out to French patient associations for individuals with T1D, such as the Fédération Française des Diabétiques, to request the dissemination of our recruitment announcement to their members. The announcement will also be published on social media. Recruitment will be based on an online announcement, attached in Appendix 1.
Additionally, we will propose to the Endocrinology Department at CHU Grenoble-Alpes to display the recruitment announcement in their waiting rooms to present it to their patients. If these recruitment channels do not yield a sufficient number of participants, we will expand dissemination to other hospital departments at the national level.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to determine whether dietary knowledge related to functional insulin therapy (FIT) is associated with the risk of developing eating disorders (EDs)
the correlation between the Gluciquizz score (a validated tool assessing FIT knowledge) and the risk of EDs, as measured by the DEPS-R questionnaire.
Time frame: Day 1
To determine whether dietary knowledge related to FIT is associated with the risk of EDs according to the SCOFF-F questionnaire (a validated French screening tool for EDs).
Correlation between the Gluciquizz score (validated for assessing FIT knowledge) and the risk of EDs according to the SCOFF-F questionnaire.
Time frame: Day 1
To assess whether the following factors influence the risk of developing EDs: a. Quality of life
Comparison of the following factors: quality of life (measured by ADDQoL, unit: individual weighted impact score) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).
Time frame: Day 1
To identify whether specific patient profiles at risk of developing EDs emerge based on the collected variables.
Identification of patient profiles based on the following variables: FIT knowledge (Gluciquizz, unit: percentage of correct responses), quality of life (ADDQoL, unit: individual weighted impact score), diabetes-related anxiety (PAID, unit: total score ranging from 0 to 100), fear of hypoglycemia (HFS-II, unit: total score ranging from 0 to 33 for the behavior subscale and 0 to 45 for the worry subscale), diabetes duration (unit: years), and treatment (unit: type of treatment, e.g., insulin therapy, oral antidiabetic drugs), with DEPS-R (unit: total score ranging from 0 to 30) as an illustrative variable.
Time frame: Day 1
To explore the influence of functional insulin therapy on eating behaviors through semi-structured interviews.
Insights into the decision-making factors influencing food choices among individuals with type 1 diabetes, following qualitative study methodologies.
Time frame: Day 1
To assess whether the following factors influence the risk of developing EDs: b. Diabetes-related anxiety
Comparison of the following factors: diabetes-related anxiety (PAID, unit: total score ranging from 0 to 100) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).
Time frame: Day 1
To assess whether the following factors influence the risk of developing EDs: c. fear of hypoglycemia
Comparison of the following factors: fear of hypoglycemia (HFS, unit: total score ranging from 0 to 8) between two groups defined by the DEPS-R threshold (≤ 20 vs. \> 20, indicating ED risk).
Time frame: Day 1
Started Apr 2025 (actual). Primary completion is estimated for Dec 2025, 8 months after the start.
Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's planned 8 months is below that.
Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →